Abstract 433P
Background
Previous researches have reported on the protective effect of aspirin on different types of cancers. However, evidence from observational studies can be biased by multiple confounding factors. Also, it remains unclear whether aspirin use is casually related to a decreased cancer risk. Consequently, we conducted Mendelian randomization analyses, using single nucleotide polymorphisms (SNPs) as instrumental variables to investigate the casual effect of aspirin on different types of cancers.
Methods
Mendelian randomization analyses were conducted using pooled statistics from corresponding researches and several large-scale consortia. Inverse-variance weighted, MR-Egger and weighted median methods were utilized to evaluate the possible causal relationship between aspirin and the observed reduction in cancer risk. Results were shown by odds ratios (OR) and their corresponding 95% CIs. Analyses were conducted using the package “TwoSampleMR” in R.
Results
A total of 19 cancers corresponding to 344,392 cases and 5,424,758 controls were included in the final analysis. In contrast to the lower risk for various cancer types reported in conventional observational studies, our MR results only showed a decreased risk in lung cancer [odds ratio (OR) 0.0418; 95% confidence interval (CI) 0.0031-0.5638; P=0.0168] and squamous cell lung cancer [OR=0.002; 95% CI 1.2145×10-5-0.3009; P=0.0153]. Insignificant results were observed in other types of cancers including lung adenocarcinoma, breast cancer, ovarian cancer, colon cancer, kidney cancer, liver cancer, esophageal cancer, oral cancer, pancreas cancer, rectal cancer, malignant melanoma, non-melanoma skin cancer, Hodgkin’s lymphoma as well as non-Hodgkin’s lymphoma.
Conclusions
The potential effect of aspirin in cancer prevention still needs to be interpreted with cautions and aspirin is still too early to be recommended as a universal chemoprotective agent for primary cancer prevention. Further randomized controlled trials with a more rigorous design are warranted in the future.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
243P - Target sequencing of 508 genes in Chinese epithelial ovarian cancer patients
Presenter: Li Lei
Session: e-Poster Display Session
244P - Optimization of early diagnostics of cervical intraepitelial neoplasies and cervical cancer
Presenter: Zakhirova Nargiza
Session: e-Poster Display Session
245P - Clinicopathological features including response to platinum-based chemotherapy in endometrial carcinomas involving SWI/SNF complex inactivation.
Presenter: Izumi Tanimoto
Session: e-Poster Display Session
246P - Impact of genetically predicted elevated concentrations of C-reactive protein on ovarian cancer risk: A Mendelian randomization study
Presenter: Haoxin Peng
Session: e-Poster Display Session
247P - The role of p53 gene suppressor and bcl-2 oncoprotein in non-epithelial ovarian tumor prognosis determination among child and adolescent patients
Presenter: Anvar Shukullaev
Session: e-Poster Display Session
248P - The effect of progesterone on ALA-based PDT efficacy in uterine sarcoma cells
Presenter: Ellie Chu
Session: e-Poster Display Session
249P - A Retrospective Study on the Treatment Response of Locally Advanced Cervical Cancer Patients to Combination Chemoradiotherapy
Presenter: Siti Nabihah Sahralidin
Session: e-Poster Display Session
250P - Health-related Quality of Life in Women with Cervical Cancer
Presenter: Almagul Zhabagina
Session: e-Poster Display Session
251P - Tendency of morbidity and mortality in cervical cancer in the last 10 years in the Republic of Uzbekistan
Presenter: Mirzagaleb Tillyashaykhov
Session: e-Poster Display Session
252P - Secondary data analysis of newly diagnosed advanced ovarian cancer in South Korea
Presenter: Soo Young Jeong
Session: e-Poster Display Session